Adaptive Biotechnologies (FRA:1HM) 3-Year Revenue Growth Rate : 16.30% (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Adaptive Biotechnologies 3-Year Revenue Growth Rate?

Adaptive Biotechnologies's Revenue per Share for the three months ended in Mar. 2024 was €0.26.

During the past 12 months, Adaptive Biotechnologies's average Revenue per Share Growth Rate was -6.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was 16.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was 14.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 7 years, the highest 3-Year average Revenue per Share Growth Rate of Adaptive Biotechnologies was 27.90% per year. The lowest was 1.90% per year. And the median was 21.85% per year.

Competitive Comparison of Adaptive Biotechnologies's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Adaptive Biotechnologies's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adaptive Biotechnologies's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptive Biotechnologies's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Adaptive Biotechnologies's 3-Year Revenue Growth Rate falls into.

Adaptive Biotechnologies 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Adaptive Biotechnologies (FRA:1HM) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Adaptive Biotechnologies 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Adaptive Biotechnologies's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Adaptive Biotechnologies (FRA:1HM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptive Biotechnologies Corp (FRA:1HM) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

ADPT:USA 1HM:Germany

Address

1165 Eastlake Avenue East, Seattle, WA, USA, 98109

Website

https://www.adaptivebiotech.com

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease ("MRD") in patients with multiple myeloma ("MM"), B cell acute lymphoblastic leukemia ("ALL") and chronic lymphocytic leukemia ("CLL") and is also available as a CLIA-validated laboratory developed test ("LDT") for patients with other lymphoid cancers, including diffuse large B-cell lymphoma ("DLBCL").

Adaptive Biotechnologies (FRA:1HM) Headlines

No Headlines